A Phase 1b, Multicenter, Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Tegoprubart (AT-1501) in Patients Undergoing Kidney Transplantdoi:10.1681/ASN.20223311S1967cJean TchervenkovMcGill University Faculty of Medicine and Health Sciences, Montreal, QC, CanadaPatrick T....
About Eledon Pharmaceuticals and Tegoprubart (formerly AT-1501) Eledon Pharmaceuticals is a clinical stage biotechnology company with immunology expertise that is developing therapies to protect and prevent rejection of transplanted organ...